PT2740793T - Composição de fármacos para o tratamento e/ou a prevenção de cancro - Google Patents

Composição de fármacos para o tratamento e/ou a prevenção de cancro

Info

Publication number
PT2740793T
PT2740793T PT128197597T PT12819759T PT2740793T PT 2740793 T PT2740793 T PT 2740793T PT 128197597 T PT128197597 T PT 128197597T PT 12819759 T PT12819759 T PT 12819759T PT 2740793 T PT2740793 T PT 2740793T
Authority
PT
Portugal
Prior art keywords
prevention
cancer treatment
drug composition
drug
composition
Prior art date
Application number
PT128197597T
Other languages
English (en)
Inventor
Okano Fumiyoshi
Kobayashi Shinichi
Saito Takanori
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PT2740793T publication Critical patent/PT2740793T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT128197597T 2011-08-04 2012-08-03 Composição de fármacos para o tratamento e/ou a prevenção de cancro PT2740793T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011171332 2011-08-04

Publications (1)

Publication Number Publication Date
PT2740793T true PT2740793T (pt) 2018-02-23

Family

ID=47629406

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128197597T PT2740793T (pt) 2011-08-04 2012-08-03 Composição de fármacos para o tratamento e/ou a prevenção de cancro

Country Status (17)

Country Link
US (1) US9181334B2 (pt)
EP (1) EP2740793B1 (pt)
JP (1) JP6015448B2 (pt)
KR (1) KR101968498B1 (pt)
CN (1) CN103717738B (pt)
AU (1) AU2012290955B2 (pt)
BR (1) BR112014002621B1 (pt)
CA (1) CA2844038C (pt)
DK (1) DK2740793T3 (pt)
ES (1) ES2660115T3 (pt)
HU (1) HUE035689T2 (pt)
MX (1) MX348579B (pt)
PL (1) PL2740793T3 (pt)
PT (1) PT2740793T (pt)
RU (1) RU2624049C2 (pt)
TR (1) TR201802089T4 (pt)
WO (1) WO2013018892A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
PL2532743T3 (pl) * 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
AU2012290949B2 (en) * 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR102005786B1 (ko) 2012-02-21 2019-07-31 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112014023937A2 (pt) * 2012-03-30 2018-04-17 Toray Industries composição farmacêutica, agente farmacêutico de combinação e método de tratamento
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
CN104471403B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
PL3587448T3 (pl) * 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
MX360671B (es) 2013-08-09 2018-11-13 Toray Industries Composición farmacéutica para el tratamiento y/o prevención del cáncer.
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
KR20170084326A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Cd3 및 종양 항원과 결합하는 이종이량체 항체
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
BR112019008335A2 (pt) 2016-10-28 2020-01-28 Toray Industries conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
MX2020009862A (es) 2018-03-30 2020-10-08 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
MX2021015221A (es) 2019-06-13 2022-03-17 Bolt Biotherapeutics Inc Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
CN114746404A (zh) 2019-09-30 2022-07-12 博尔特生物治疗药物有限公司 酰胺连接的氨基苯并氮杂䓬免疫缀合物及其用途
WO2021081407A1 (en) 2019-10-25 2021-04-29 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
JPWO2021182574A1 (pt) 2020-03-12 2021-09-16
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20220153621A (ko) 2020-03-12 2022-11-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4196168A1 (en) 2020-08-13 2023-06-21 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
KR20240024074A (ko) 2021-06-23 2024-02-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN117460532A (zh) 2021-06-23 2024-01-26 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378477A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
IL140845A0 (en) 1998-07-14 2002-02-10 Corixa Corp Compositions for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003528587A (ja) 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 27個のヒト分泌タンパク質
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
PL366626A1 (en) 2000-03-29 2005-02-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP1516049A4 (en) 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
EP2481814A3 (en) 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
JP2008506352A (ja) 2004-01-26 2008-03-06 デビオビジョン・インコーポレーテッド 新生物特異的ポリペプチド及びその使用
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
WO2006099126A2 (en) 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
DK2325648T3 (da) * 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
JP5734978B2 (ja) 2009-08-19 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Ffpe材料におけるインテグリン複合体検出のための抗体
WO2011035884A1 (en) 2009-09-22 2011-03-31 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
ES2691738T3 (es) 2010-02-04 2018-11-28 Toray Industries, Inc. Agente farmacéutico para el tratamiento y/o la prevención de cáncer
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532743T3 (pl) 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PT2532680E (pt) 2010-02-04 2015-09-14 Toray Industries Composição medicinal para tratar e/ou prevenir o cancro
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
BR112014023937A2 (pt) 2012-03-30 2018-04-17 Toray Industries composição farmacêutica, agente farmacêutico de combinação e método de tratamento
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar

Also Published As

Publication number Publication date
EP2740793A1 (en) 2014-06-11
AU2012290955A1 (en) 2014-03-20
CA2844038A1 (en) 2013-02-07
BR112014002621B1 (pt) 2022-09-20
KR101968498B1 (ko) 2019-04-12
JPWO2013018892A1 (ja) 2015-03-05
CN103717738A (zh) 2014-04-09
CA2844038C (en) 2019-05-07
ES2660115T3 (es) 2018-03-20
EP2740793B1 (en) 2017-11-29
DK2740793T3 (en) 2018-01-22
US20140199311A1 (en) 2014-07-17
WO2013018892A1 (ja) 2013-02-07
MX2014001373A (es) 2014-05-21
PL2740793T3 (pl) 2018-04-30
KR20140054186A (ko) 2014-05-08
HUE035689T2 (en) 2018-05-28
RU2624049C2 (ru) 2017-06-30
BR112014002621A2 (pt) 2017-12-12
RU2014108042A (ru) 2015-09-10
US9181334B2 (en) 2015-11-10
AU2012290955B2 (en) 2017-04-27
MX348579B (es) 2017-06-20
JP6015448B2 (ja) 2016-10-26
CN103717738B (zh) 2015-07-15
EP2740793A4 (en) 2015-04-01
TR201802089T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
PT2818481T (pt) Composição farmacêutica para tratamento e/ou prevenção de cancro
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2818483A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2740489A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA
PT2832366T (pt) Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2832365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF LIVER CANCER
EP2740796A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE039219T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PL2532367T3 (pl) Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu
EP2709614A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer